newsfilter
← Latest News
GlobeNewswire·

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer